CN114177208A - Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine - Google Patents
Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine Download PDFInfo
- Publication number
- CN114177208A CN114177208A CN202210083489.8A CN202210083489A CN114177208A CN 114177208 A CN114177208 A CN 114177208A CN 202210083489 A CN202210083489 A CN 202210083489A CN 114177208 A CN114177208 A CN 114177208A
- Authority
- CN
- China
- Prior art keywords
- ethanol extract
- custard
- weight
- custard apple
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000469 ethanolic extract Substances 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 244000028821 Annona squamosa Species 0.000 title abstract description 42
- 235000005274 Annona squamosa Nutrition 0.000 title abstract description 42
- 235000002272 Annona cherimola Nutrition 0.000 title abstract description 30
- 235000005288 Annona lutescens Nutrition 0.000 title abstract description 30
- 238000002360 preparation method Methods 0.000 title abstract description 5
- 239000000284 extract Substances 0.000 claims abstract description 6
- 235000011950 custard Nutrition 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000001035 drying Methods 0.000 claims description 6
- 244000062241 Kaempferia galanga Species 0.000 claims description 4
- 235000013421 Kaempferia galanga Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 210000002966 serum Anatomy 0.000 abstract description 16
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 14
- 208000008589 Obesity Diseases 0.000 abstract description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 12
- 235000020824 obesity Nutrition 0.000 abstract description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
- 230000037396 body weight Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 230000002588 toxic effect Effects 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 25
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 238000012360 testing method Methods 0.000 description 14
- 229940079593 drug Drugs 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 206010033307 Overweight Diseases 0.000 description 5
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 210000002216 heart Anatomy 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000013116 obese mouse model Methods 0.000 description 5
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- 102000019280 Pancreatic lipases Human genes 0.000 description 3
- 108050006759 Pancreatic lipases Proteins 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 239000002830 appetite depressant Substances 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000020828 fasting Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000004279 orbit Anatomy 0.000 description 3
- 229940116369 pancreatic lipase Drugs 0.000 description 3
- 229920001992 poloxamer 407 Polymers 0.000 description 3
- 229940044476 poloxamer 407 Drugs 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 102000014898 transaminase activity proteins Human genes 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 241000722951 Annona Species 0.000 description 2
- 235000007755 Annona Nutrition 0.000 description 2
- 235000011518 Annona purpurea Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 229940109239 creatinine Drugs 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000000556 factor analysis Methods 0.000 description 2
- 201000005577 familial hyperlipidemia Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- -1 AST Proteins 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000000412 Avitaminosis Diseases 0.000 description 1
- PWDLDBWXTVILPC-WGAVTJJLSA-N CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 Chemical compound CC(C)(N)CC1=CC=CC=C1.C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PWDLDBWXTVILPC-WGAVTJJLSA-N 0.000 description 1
- 241000606540 Chione venosa Species 0.000 description 1
- 208000031288 Combined hyperlipidaemia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021135 Hypovitaminosis Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000014590 basal diet Nutrition 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 201000001883 cholelithiasis Diseases 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 235000019626 lipase activity Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- XTTZERNUQAFMOF-QMMMGPOBSA-N lorcaserin Chemical compound C[C@H]1CNCCC2=CC=C(Cl)C=C12 XTTZERNUQAFMOF-QMMMGPOBSA-N 0.000 description 1
- 229960005060 lorcaserin Drugs 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 229960001243 orlistat Drugs 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940103440 qsymia Drugs 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000030401 vitamin deficiency disease Diseases 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/15—Preparation or pretreatment of starting material involving mechanical treatment, e.g. chopping up, cutting or grinding
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/17—Preparation or pretreatment of starting material involving drying, e.g. sun-drying or wilting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a new application of an ethanol extract of custard apple, namely the application in preparing a medicament for reducing fat and losing weight. The extract has simple preparation method, can remarkably reduce serum total cholesterol and triglyceride, and reduce body weight, and has remarkable effect and no toxic and side effects. The invention provides the new medical application of the custard apple ethanol extract, can obviously increase the economic additional value of custard apple, and has good economy; but also provides a new idea for treating hyperlipidemia and obesity, and has good social benefit.
Description
Technical Field
The invention relates to application of an ethanol extract of custard Galangal, in particular to application of the ethanol extract of custard Galangal in preparing a lipid-lowering and weight-losing medicine.
Background
A higher than normal level of one or more lipids in plasma due to abnormal fat metabolism or movement is called hyperlipidemia. Hyperlipidemia is usually more secret and generally can not be found, and is more serious when finding. Hyperlipidemia is a major risk factor for atherosclerotic diseases in humans. Like common atherosclerotic diseases are: coronary heart disease (including myocardial infarction, angina pectoris and sudden death), cerebral infarction and peripheral vascular thromboembolic diseases. The cardiovascular and cerebrovascular diseases have high morbidity, great harm and serious disease progression, and the death rate of the cardiovascular and cerebrovascular diseases accounts for about half of the total death rate of human beings. Obesity refers to a condition of excess accumulation of body fat, especially triglycerides, due to a degree of significant overweight and an excessively thick fat layer. Excessive accumulation of fat in the body due to excessive food intake or altered metabolism of the body causes excessive weight gain and causes pathological, physiological changes or latency in the human body. The World Health Organization (WHO) has formally defined obesity as a disease for a long time. According to research data, the incidence rate and the growth speed of overweight and obesity in China are at the first place in the world, and the number of people who are overweight and obese is at the first place in the world. In the adults in China, on average, one overweight patient exists in every 5 adults, and one obese patient exists in every 9 adults in clinical significance. In 2019, overweight/obesity is the sixth leading lethal and disabling risk factor in our country. Obesity not only affects body beauty and brings inconvenience to life, but also increases the risk of cardiovascular diseases, affects the functions of the digestive system and the endocrine system, and increases the risk of cancer. Therefore, the lipid-lowering weight-losing medicine has good market prospect and social benefit.
The lipid-lowering drugs which are commonly used clinically at present comprise: (1) statins: statins are the best drugs for treating hypercholesterolemia and combined hyperlipidemia, but have common side effects, such as rise of transaminase, liver damage, myopathy, rise of blood sugar and increase of incidence rate of diabetes, and memory and cognitive dysfunction caused by long-term statin administration; (2) nicotinic acids: nicotinic acid drugs are the oldest lipid regulating drugs, are the drugs with the best effect of increasing high density lipoprotein cholesterol, and are particularly suitable for reducing the high density lipoprotein cholesterol or increasing combined triglyceride. But the adverse reactions are more, including liver poisoning, hyperglycemia, peptic ulcer, ventilation and the like can occur; (3) the fibrate drugs are lipid regulators which are widely applied at present, are lipid-lowering drugs with the best effect of lowering triglyceride, have slight side effects after short-term administration, mainly cause gastrointestinal reactions such as abdominal distension, diarrhea and the like, and occasionally have symptoms such as headache, hypodynamia, rash, blurred vision and the like, and can increase transaminase and increase the incidence rate of gallstones after long-term administration. Patients with liver, gallbladder or severe kidney diseases should not use the original drugs.
The weight loss drugs currently on the market fall into two broad categories, pancreatic lipase inhibitors and appetite suppressants acting on the central nervous system. Appetite suppressants are limited in use because they cause adverse reactions in the nervous system, and the pancreatic lipase inhibitor orlistat is used for weight reduction by inhibiting pancreatic lipase activity and thus inhibiting the decomposition and absorption of fat in food. But it can cause fat diarrhea and can cause fat-soluble vitamin deficiency. It has also recently been reported to cause liver function damage. Although the central nervous system appetite suppressants lorcaserin and Qsymia became the first approved weight loss drugs by FDA for 13 years, they still have safety uncertainties in the central brain and cardiovascular system.
Therefore, the search for safe and effective lipid-lowering and weight-losing drugs is always an important task for medical workers.
Annona squamosa Linn, Annona squamosa, is a small tree of Annona squamosa, Annona, and is cultivated in Zhejiang, Taiwan, Fujian, Guangdong, Guangxi, Hainan, and Yunnan provinces. The fruit is edible, is a famous fruit in tropical regions, and contains 2.34% of protein, 0.3% of fat and 20.42% of carbohydrate; the oil content of the seeds reaches 20 percent. The bark fiber can be used for making paper. The medicine can be used for treating acute dysentery, mental depression and spinal cord osteopathia; the fruit can be used for treating sore and swelling pain, and invigorating spleen. The custard apple has the effect of activating brain cells and is commonly used for treating encephalatrophy outside China. In addition, the custard apple has high fiber content, can effectively promote intestinal peristalsis and remove stubborn stool accumulated in intestines, and is also the best antioxidant fruit, so that the custard apple can effectively delay skin aging and whiten skin. Inside the custard apple there are many black seeds, which are usually discarded. The custard does not contain toxic substances, and even if the custard is eaten by mistake, the custard does not cause toxic reaction. Besides being used for raising seedlings, making hand strings and serving as fertilizer, the research and development on the pharmacological activity and application of the custard apple is still blank, and the custard apple with relatively high price is a waste of resources.
Disclosure of Invention
Aiming at the situations, in order to overcome the defects of the prior art, the invention aims to develop the new application of the custard, realize waste utilization and provide a new lipid-lowering and weight-losing therapeutic drug.
In order to achieve the purpose, the invention provides the application of the ethanol extract of custard apple in preparing the lipid-lowering and weight-losing medicines.
The invention solves the technical scheme that the application of the custard apple nuclear ethanol extract in preparing the lipid-lowering and weight-losing medicine is characterized in that the custard apple nuclear ethanol extract is obtained by adopting the following extraction method: taking custard, drying, crushing, sieving, placing in a round-bottom flask, adding 12 times of 75% ethanol by volume, heating and refluxing for 3h, filtering to obtain filtrate, placing in a rotary evaporator to recover ethanol until no ethanol smell exists, continuing to concentrate into extract, and drying under reduced pressure to obtain brown yellow powder.
Compared with the prior art, the invention has the following advantages:
the invention provides the application of the ethanol extract of the custard apple in preparing the lipid-lowering and weight-losing medicines, the raw materials are rich, the preparation method is simple, the total cholesterol and triglyceride in serum can be obviously reduced, the weight is reduced, the effect is obvious, and no toxic or side effect exists. The invention provides a new medical application of the custard apple ethanol extract, can realize waste utilization, obviously increases the economic additional value of custard apple, and has good economic benefit; but also provides a new idea for treating hyperlipidemia and obesity, and has good social benefit.
Drawings
FIG. 1 shows the effect of ethanol extract of custard apple on the tissue structure of heart, liver, spleen, lung and kidney of mice.
Detailed Description
The present invention will be described in detail with reference to specific examples.
Example 1 preparation of Annona Sakyamuni Kernel ethanol extract
Taking custard, drying, weighing 100g, crushing, sieving, placing in a 2000mL round-bottom flask, adding 1200mL of ethanol with 75% volume fraction, placing on an electric heating jacket, heating, refluxing and extracting for 3h, filtering with gauze to obtain filtrate, placing in a rotary evaporator, recovering ethanol until no alcohol smell exists, continuing to concentrate into extract, and drying under reduced pressure to obtain 12.3g of brown yellow powder.
The invention further describes the effect of reducing fat and losing weight through test examples, and has good safety.
Test example 1 therapeutic Effect of Annona squamosa Kernel ethanol extract on acute hyperlipidemic mouse
1. Test materials
The ethanol extract of custard Galamina prepared by the embodiment is respectively dissolved by normal saline to prepare solutions of 0.5mg/mL, 1mg/mL and 2 mg/mL;
poloxamer 407, basf, germany;
serum Total Cholesterol (TC) and Triglyceride (TG)2 kit, Nanjing institute of bioengineering;
clean-grade Kunming mice, with the body mass of 18-22 g and half male and female, are provided by Qingdao Daren Fucheng livestock Limited and are used for experiments after being fed for 7 days in an adaptive manner.
2. Test method
40 mice were randomly assigned to 5 groups (n-8): control group, hyperlipemia group, small, medium and large dosage group of custard apple seed ethanol extract. The small, medium and large dose of the ethanol extracts of the custard apple are respectively gavaged with 0.5mg/mL, 1mg/mL and 2mg/mL of the ethanol extracts of the custard apple 0.1mL/10g for 1 time per day for 3 days, and the mice of the control group and the poloxamer group are gavaged with the same amount of physiological saline. After the last administration for 3h, except for the control group which is injected with normal saline with the same amount, other groups of mice are injected with 30mg/mL poloxamer 4070.1mL/10g in the abdominal cavity. Fasting is carried out on the day, blood is taken from the eye orbit of the mouse after 24h, serum is taken by centrifuging at 3500r/min for 10min, and the TC and TG contents of the serum are determined by adopting a kit.
The experimental data are expressed as mean ± standard deviation, and single factor analysis of variance using SPSS17.0, P <0.05 is considered statistically significant.
3. Test results
The test results are shown in Table 1. The experiment adopts a method of injecting poloxamer 407 into the abdominal cavity to prepare a mouse acute hyperlipidemia model, and the result shows that the TC and TG levels of serum of a mouse in a hyperlipidemia group are obviously increased (P is less than 0.01) compared with those of a control group after injecting poloxamer 407 into the abdominal cavity, thereby prompting the successful establishment of the hyperlipidemia model. After mice are given with different doses of the ethanol extract of the custard apple tree seeds, the serum TC and TG levels are reduced to different degrees (compared with a hyperlipemia group, P is less than 0.01), and a dose dependence relationship is shown, wherein the large dose of the ethanol extract of the custard apple tree seeds has no significant difference (P is more than 0.05) compared with a control group.
TABLE 1 Effect of Annona squamosa Kernel ethanol extract on the blood lipid level of hyperlipidemic mice
Note: compared with the control group, the compound of the formula,*P<0.05，**P<0.01; compared with the group with high blood fat,△P<0.01; compared with the group of small dose,▲P<0.01; in comparison with the medium dose group,#P<0.01。
4. conclusion
The ethanol extract of Annona squamosa has blood lipid reducing activity, and can be used for treating hyperlipidemia.
Test example 2 therapeutic Effect of Annona squamosa Kernel ethanol extract on obese mice
1. Test materials
The ethanol extract of custard Galamina prepared by the embodiment is respectively dissolved by normal saline to prepare solutions of 0.5mg/mL, 1mg/mL and 2 mg/mL;
the high-fat feed is prepared by self, and the formula of the high-fat feed is as follows: 88% basal feed + 2% cholesterol + 10% lard;
cholesterol, food grade, Jiangsu Xin and Source Biotech, Inc.;
lard, which is prepared by boiling commercial fat pork;
basal feed, livestock limited of great-grained great-chang of Qingdao;
serum Total Cholesterol (TC) and Triglyceride (TG) kit, Nanjing institute of bioengineering;
clean-grade Kunming mice, with the body mass of 18-22 g and half male and female, are provided by Qingdao Daren Fucheng livestock Limited and are used for experiments after being fed for 7 days in an adaptive manner.
2. Test method
40 mice were taken and randomly divided into 5 groups (n ═ 8): control group, obesity group, small, medium and large dosage group of custard apple seed ethanol extract. The small, medium and large dose mice of the custard apple nuclear ethanol extract are respectively gavaged with 0.5mg/mL, 1mg/mL and 2mg/mL of the custard apple nuclear ethanol extract 0.1mL/10g, and the mice of the control group and the obese group are gavaged with the same amount of normal saline for 1 time per day for 8 weeks. During the period, the group was fed with high fat diet except for the basal diet of the control group. Fasting the mice for 12h after the last administration, weighing, taking blood from eye sockets, centrifuging at 3500r/min for 10min, taking serum, and determining the content of TC and TG in the serum by using a kit; after the mice die after dislocation, the heart, liver, spleen and kidney are taken, the wet weight is weighed after the blood is sucked dry, and the organ coefficient is calculated by the following formula: organ coefficient is organ wet weight/body weight.
The experimental data are expressed as mean ± standard deviation, and single factor analysis of variance using SPSS17.0, P <0.05 is considered statistically significant.
3. Test results
The test results are shown in tables 2 and 3. According to the experiment, a mouse obesity model is established by adopting a high-fat feed feeding method, and the results show that after the mouse is fed with the high-fat feed for 8 weeks, the serum TC and TG levels of mice in an obesity group are obviously increased (compared with a control group, P is less than 0.01), the body weight is obviously increased (compared with the control group, P is less than 0.01), the organ coefficients of the heart, the liver, the spleen and the kidney are all increased (compared with the control group, P is less than 0.01), and the success of establishing the obesity model is prompted. After the mice are fed with high-fat feed and simultaneously fed with different doses of the ethanol extract of the custard's nits, the serum TC and TG levels of the mice are obviously reduced (P <0.01) compared with the obese mice, the body weight is obviously reduced (P <0.01), the coefficients of various organs are reduced to different degrees (P <0.05 or P <0.01), and the dose-dependent relationship is shown, wherein the large-dose ethanol extract of the custard's nits has no obvious difference (P >0.05) compared with the control group.
TABLE 2 Effect of Annona squamosa Kernel ethanol extract on blood lipid levels in obese mice
Note: compared with the control group, the compound of the formula,*P<0.01; in comparison with the obese group,△P<0.01; compared with the group of small dose,▲P<0.01; in comparison with the medium dose group,#P<0.05。
TABLE 3 Effect of Annona squamosa Kernel ethanol extract on body weight and organ coefficients of obese mice
Note: compared with the control group, the compound of the formula,*P<0.05，**P<0.01; in comparison with the obese group,△P<0.05，△△P<0.01; compared with the small-dose custard water extract group,▲P<0.05，▲▲P<0.01; comparing with the middle-dose custard water extract group,#P<0.05，##P<0.01。
4. conclusion
The ethanol extract of custard Galamina can inhibit the increase of blood lipid level, weight gain and organ enlargement of obese mice, and can be used for treating obesity.
Test example 3 acute toxic Effect of Annona squamosa Kernel ethanol extract on mice
1. Test materials
The ethanol extract of custard apple prepared by the embodiment is dissolved by normal saline, and the maximum concentration of the liquid medicine of the ethanol extract of custard apple, which is difficult to absorb but not impossible to absorb, is 0.35g/mL by a gastric lavage needle test.
Clean-grade Kunming mice, with the body mass of 18-22 g and half male and female, are provided by Qingdao Daren Fucheng livestock Limited and are used for experiments after being fed for 7 days in an adaptive manner.
Serum alanine Aminotransferase (ALT), aspartate Aminotransferase (AST), urea nitrogen (BUN) and creatinine (Cr) kit, Nanjing institute of bioengineering;
HE staining kit: beijing Boaosen Biotechnology Ltd.
2. Test method
Because the experiment does not show LD50 due to the limitation of drug concentration and volume, the maximum dose method is adopted. 20 mice were taken and randomly divided into two groups: control group and administration group. After fasting and water prohibition for 12h, mice in the administration group were gavaged with the maximum gavage concentration of the ethanol extract of custard's nuclear (0.35g/mL) according to the maximum administration volume (0.4mL/10g), and the control group was given with the same amount of physiological saline for 1 time. After administration, mice were observed for activity, diet, feces, respiration, body weight and death for 14 days. 14d, fasting for 12h, weighing, taking blood from an orbit, taking a drop of whole blood, counting the number of Red Blood Cells (RBC), White Blood Cells (WBC) and Platelets (PLT) by using a blood cell counting plate, centrifuging the rest blood at 3500r/min for 10min, taking serum, and measuring the content of serum alanine Aminotransferase (ALT), glutamic-oxalacetic transaminase (AST), urea nitrogen (BUN) and creatinine (Cr) by using the kit; mice are dislocated and sacrificed, the thoracic cavity and the abdominal cavity are opened, the appearance change of important visceral organs is observed, the heart, the liver, the spleen, the lung and the kidney are subjected to routine paraffin section HE staining, and the pathological change is observed.
The experimental data are expressed as mean ± standard deviation, with independent sample t-test using SPSS17.0, P <0.05 considered statistically significant.
3. Test results
The test results are shown in table 4, table 5 and fig. 1. The results show that the ethanol extract of the custard apple with the maximum dose is given to the mice, the mice do not die, the general states of the mice are good, the food, respiration, stool and urine and the body weight are not abnormal, the RBC, WBC and PLT counts of the mice have no obvious change, the ALT, AST, BUN and Cr levels of the serum have no obvious change, and the paraffin sections of the heart, liver, spleen, lung and kidney of important organs have no obvious pathological damage.
TABLE 4 Effect of Annona squamosa Kernel ethanol extract on mouse blood routine
TABLE 5 Effect of Annona squamosa Kernel ethanol extract on blood biochemical index of mice
4. Conclusion
The ethanol extract of the custard apple has no obvious damage to mice and good safety.
Claims (1)
1. The application of the ethanol extract of custard Galangal in preparing the lipid-lowering and weight-losing medicine is characterized in that the ethanol extract of custard Galangal is obtained by adopting the following extraction method: taking custard, drying, crushing, sieving, placing in a round-bottom flask, adding 12 times of 75% ethanol by volume, heating and refluxing for 3h, filtering to obtain filtrate, placing in a rotary evaporator to recover ethanol until no ethanol smell exists, continuing to concentrate into extract, and drying under reduced pressure to obtain brown yellow powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210083489.8A CN114177208A (en) | 2022-01-24 | 2022-01-24 | Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210083489.8A CN114177208A (en) | 2022-01-24 | 2022-01-24 | Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114177208A true CN114177208A (en) | 2022-03-15 |
Family
ID=80606962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210083489.8A Pending CN114177208A (en) | 2022-01-24 | 2022-01-24 | Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114177208A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140056987A1 (en) * | 2011-04-29 | 2014-02-27 | Laila Nutraceuticals | Compositions comprising extracts or fractions derived from annona squamosa for the prevention, treatment or control of inflammatory and metabolic disorders |
| CN111317750A (en) * | 2020-02-17 | 2020-06-23 | 江苏卫生健康职业学院 | Application of sweetsop seed total lactone in preparing medicine for preventing and treating diabetes |
-
2022
- 2022-01-24 CN CN202210083489.8A patent/CN114177208A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140056987A1 (en) * | 2011-04-29 | 2014-02-27 | Laila Nutraceuticals | Compositions comprising extracts or fractions derived from annona squamosa for the prevention, treatment or control of inflammatory and metabolic disorders |
| CN111317750A (en) * | 2020-02-17 | 2020-06-23 | 江苏卫生健康职业学院 | Application of sweetsop seed total lactone in preparing medicine for preventing and treating diabetes |
Non-Patent Citations (3)
| Title |
|---|
| 唐迪等: "番荔枝籽中脂肪酸的提取和气相色谱-质谱联用分析", 《食品科学》 * |
| 林燕文: "热带名果――番荔枝及其在食品工业中的应用现状和开发前景", 《江苏食品与发酵》 * |
| 林燕文: "番荔枝及其在食品工业中的应用现状和开发前景", 《山西食品工业》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105169203B (en) | A kind of Fructus Amomi extract and application thereof | |
| CN105395919B (en) | It is a kind of to contain black fungus extract, the composition with effect for reducing blood fat and preparation method thereof | |
| Wu et al. | Hypoglycemic effect of okra aqueous extract on streptozotocin-induced diabetic rats | |
| CN103652552A (en) | Functional food with effects of reducing lipid and preventing fatty liver | |
| CN101836725A (en) | Application of red rice residue product in preparing health-care food for lowering blood fat | |
| CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
| CN105983016B (en) | A pharmaceutical composition containing silybin | |
| CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN112089784A (en) | Application of traditional Chinese medicine composition in preparation of medicine for preventing and treating diseases caused by atherosclerosis | |
| CN107551001A (en) | A kind of Chinese herbal compounds and its preparation method for being used to prevent and treat alcoholic liver injury | |
| CN106983746A (en) | A kind of medical composition and its use | |
| KR100733984B1 (en) | A pharmaceutical composition having effects of cure and prevention of obesity and hyperlipidemia by containing konjac and extract of medicinal herbs | |
| CN114177208A (en) | Application of custard apple seed ethanol extract in preparation of lipid-lowering and weight-losing medicine | |
| CN108420890A (en) | A kind of composition and preparation method thereof with effect for reducing blood fat | |
| CN100579564C (en) | Medicine for curing gout and its preparing method | |
| CN104288566B (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
| CN102793891B (en) | Traditional Chinese medicine composition having functions of reducing blood fat and resisting hyperuricemia | |
| CN110680850A (en) | Traditional Chinese medicine health product for reducing blood fat | |
| CN105193993B (en) | A kind of Chinese medicine composition with blood fat reducing function and preparation method thereof and purposes | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| CN103877152B (en) | Compositionss containing granada seed oil and Oleum Perillae, Preparation Method And The Use | |
| CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
| CN109528929A (en) | A kind of Traditional Chinese medicine compound composition and the preparation method and application thereof | |
| CN113694105B (en) | Composition with blood fat reducing function and application thereof | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220315 |
|
| WD01 | Invention patent application deemed withdrawn after publication |